2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Melanoma
26
Neuroblastoma
25
Breast Neoplasms
20
Prostatic Neoplasms
18
Leukemia
15
Multiple Myeloma
14
Lymphoma
14
Leukemia, Myeloid, Acute
14
Glioblastoma
14
Lymphoma, Non-Hodgkin
10
Neoplasms
9
Ovarian Neoplasms
8
Neoplasm Metastasis
8
Leukemia, Lymphocytic, Chronic, B-Cell
8
Colorectal Neoplasms
8
Carcinoma, Non-Small-Cell Lung
8
Breast Neoplasms, Male
8
Myelodysplastic Syndromes
7
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
7
Glioma
7
Precursor Cell Lymphoblastic Leukemia-Lymphoma
6
Fallopian Tube Neoplasms
6
Osteosarcoma
5
Hodgkin Disease
5
Carcinoma, Renal Cell
5
Brain Neoplasms
5
Uveal Melanoma
4
Recurrence
4
Rectal Neoplasms
4
Medulloblastoma
4
Interventions
sargramostim
1
Vaccines
1
Temozolomide
1
Papillomavirus Vaccines
1
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Tetanus
×
Granulocyte-Macrophage Colony-Stimulating Factor
×
Clear all
NCT03927222
2024-04-08
I-ATTAC
Duke University
Phase 2
Terminated
6 enrolled
7 charts